Hint mode is switched on Switch off

Insmed, ordinary share
INSM, US4576693075

Add a stock to WL
Insmed, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in
API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds
  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company’s lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients ...
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company’s lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex. Its earlier-stage clinical pipeline also includes INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug for rare pulmonary disorders.
  • Issuer
  • Full borrower / issuer name
    Insmed Incorporated
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    INSM
  • Placement
    07.09.2017
  • Lock up period
    180
  • Number of papers
    12,281,000
  • Volume of raised funds
    350.01 mln USD
  • Placement share
    16.45%
  • Final placement price
    28.5 USD
  • Price change since placement date
    246.7%
  • By capitalization
    2,127.74 mln USD

Related Stock indices

Registration is required to get access.